New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

Bien que son rôle exact reste inconnu, la lipoprotéine(a) — particule de LDL-cholestérol liée à une molécule proche du ...